← All trials
NCT02474589
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 19, 2015
- Primary completion
- Aug 24, 2016
- Completion date
- Aug 24, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 422
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- SIGA TechnologiesLead sponsor
- Department of Health and Human ServicesCollaborator
- SIGA TechnologiesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.